Purpose: To assess the prevalence of post-COVID symptoms in patients with recovered COVID-19 (nasopharyngeal RT PCR negative) who were discharged from an acute COVID care facility at a tertiary care teaching hospital in North India. Methods: This study was an observational study with retrospective data collection, conducted in the COVID follow-up clinic, a combined clinic of medicine and endocrinology. Patients discharged from the acute COVID care facility were recruited after 14 days of discharge if they fulfilled inclusion and exclusion criteria. The retrospective data was collected from the hospital records/EMR and analysed by the SPSSv23. Results: Fifty patients, who fulfilled the inclusion and exclusion criteria, were included in the study. The Mean age of patients was 53.4± 13.8 years (range 28– 77). Seventy six percent were male, and 38% had type 2 diabetes. Fever (94%), cough (78%) and breathlessness (68%), were the most common symptoms at presentation to acute care facility. Oxygen saturation at presentation had a negative correlation with D-Dimer, age, and C reactive protein. When patients were evaluated clinically, after 14 days (range 15 to 50 days) of the discharge, 82% of patients had at least one persistent symptom. Fatigue (74%) was the most common symptoms in follow-up followed by breathlessness (44%), and muscle weakness (36%). Two patients had persistent fever, even after negative RT PCR status. Conclusion: Patients discharged from the acute COVID care facility had a high prevalence of post-COVID symptoms even after 14 days.

The association between frailty and health-related quality of life (HRQoL) among Asian patients with liver cirrhosis and sarcopenia remains largely unexplored. To address this knowledge gap, we conducted a cross-sectional study involving individuals aged 32 to 69 years, all diagnosed with liver cirrhosis. The chronic liver disease questionnaire (CLDQ) was used to assess HR-QoL, the CLDQ score was used as an outcome to measure the factors related to HR-QoL, and the liver frailty index (LFI) was used to assess the frailty status. The association between the frailty status and the CLDQ summary scales was investigated using the correlation coefficient and multiple regression analyses. A total of 138 patients in the frail (n = 62) and non-frail (n = 76) groups with (alcohol: 97; viral: 24; autoimmune: 17; and cryptogenic: 12) were included in the study. Age, CTP score, and model for end-stage liver disease (MELD) sodium were significantly higher in the frail group. In the CLDQ domains, there was a significant difference between the frail and non-frail groups (p value = 0.001). In health-related quality-of-life summary measures, there was a strong negative correlation between frailty and the scores for activities, emotional function, and fatigue (p value = 0.001). When comparing frail to non-frail patients, these characteristics demonstrated significantly increased odds as indicated by their adjusted odds ratios: OR 3.339 (p value = 0.013), OR 3.998 (p value = 0.006), and OR 4.626 (p value = 0.002), respectively.

Breast cancer, a global health concern predominantly affecting women, recorded 2.3 million new cases and 685,000 deaths in 2020. Alarmingly, projections suggest that by 2040, there could be over 3 million new cases and 1 million deaths. To assess breast cancer prevalence in 24 rural villages within a 60 km radius of NIMS Hospital, Tala Mod, Jaipur, Rajasthan, North India 303,121. A study involving 2023 participants conducted initial screenings, and positive cases underwent further tests, including ultrasound, mammography, and biopsy. SPSSv28 analysed collected data. Among 2023 subjects, 3 screened positive for breast lumps. Subsequent clinical examination and biopsy identified 1 normal case and 2 with breast cancer, resulting in a prevalence proportion of 0.0009 or 98 per 100,000. This study helps fill gap in breast cancer prevalence data for rural Rajasthan. The results highlight a concerning prevalence of breast cancer in the rural area near NIMS hospital, emphasizing the urgent need for increased awareness, early detection, and better healthcare access. Challenges like limited resources, awareness programs, and delayed diagnosis contribute to this high incidence. To address this, comprehensive approach is necessary, including improved screening programs and healthcare facilities in rural areas. Prioritizing rural healthcare and evidence-based strategies can reduce the burden of breast cancer and improve health outcomes.

Introduction: The ongoing repercussions of the COVID-19 pandemic include potentially deleterious impacts on bone health. Aim: This research aimed to ascertain the effects of COVID-19 on the bone health of obese and non-obese Indian individuals. Methods: We executed a case-control study enrolling individuals who recovered from COVID-19. Participants were stratified into obese and non-obese groups based on their BMI. Comprehensive assessments encompassed anthropometric evaluations, laboratory tests, and bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry (DEXA). Results: From April to July 2022, we enrolled obese (n = 27, mean BMI = 30.54 ± 4.51 kg/m 2) and non-obese (n = 23, mean BMI = 21.97 ± 2.20 kg/m 2) individuals. The cohort’s average age was 36.08 ± 15.81 years, with a male-to-female ratio of 1.6:1. There was a difference in BMD, especially at the total hip, between the two groups. BMD at the spine (L1-L4), the neck of the femur, and ultra-distal radius were consistent across both groups. Weight exhibited a significant positive correlation with BMD at L1-L4 (r = 0.40, p = 0.003) and the left femur total (r = 0.27, p = 0.001). Haemoglobin levels were lower in the obese group compared to their non-obese counterparts (12.3 ± 2.0 vs 13.6 ± 1.9, p = 0.01). Multivariate analysis underscored weight as a crucial predictor for BMD at the spine (L1-L4, p = 0.003) and total hip (p = 0.001). Conclusion: Even with advanced age, obese post-COVID-19 individuals demonstrate a higher bone mineral density (BMD) at the hip than non-obese subjects.

Background: Frailty is a critical concern for chronic kidney disease (CKD) patients, contributing to increased vulnerability to adverse health outcomes and diminished quality of life. However, there is limited research on frailty’s impact on health-related quality of life (HRQOL) among dialysis and pre-dialysis patients in the Indian context. Methods: This study involved participants aged 18 and above with CKD stages 3–5. Frailty was assessed using the Morley FRAIL questionnaire, and HRQOL was measured using the RAND version of the KDQOL-36 Survey. Data were analyzed with SPSS version 29, focusing on the association between frailty and HRQOL domains. Results: Among the 147 CKD patients, 56.46% were frail, and 43.56% were non-frail. Significant differences were noted between frail and non-frail groups in age (p = 0.036), CKD stages (p < 0.001), nutritional status (p < 0.001), Charlson comorbidity index (p < 0.001), BMI (p < 0.001), GFR (p < 0.001), CRP (p = 0.006), and serum albumin (p = 0.002). Frailty is significantly associated with lower physical (p < 0.001) and mental (p < 0.001) quality of life. Negative associations between frailty and KDQOL-36 domains, especially symptom problems, PCS, and MCS, were established. Conclusions: Our findings emphasize the importance of frailty screening in CKD patients. Early identification may help guide targeted strategies to support HRQOL. However, longitudinal studies are needed to assess frailty progression and the impact of potential interventions.

Treatment and effective therapies of most of the neurodegenerative disease are not available due to social and economic factors which makes it incurable. Huntington’s disease is one of such disease. Huntington’s disease (HD) is an inherited condition which leads to progressive degeneration of nerve cells may leads to cognitive, behavioral, and psychiatric symptoms. Discovery of zebrafish has filled the gap between in vitro and in vivo assays and makes the study of neuroscience easy with less complications. Zebrafish model has become a recent topic to focus on, as its utility in the study of neurological disease and role in improving screening methods makes the treatment and therapies more productive. Zebrafish hold many advanced functional genomics like human disease, the understanding of genetics, neurodegenerative disease and disorders and the discovery of therapeutics. It assess the mutant gene, etiology of human’s disease, and it is role in the disease progression and allows the identification of relevant treatment for the same. This review highlights the role of the zebrafish in the Huntington’s disease.